Side-by-side · Research reference
PancragenvsSelank
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED23/39 cited
BHuman-MechanisticAUTO-DRAFTED11/40 cited
Selank
Anxiolytic + Cognitive · Russian Pharma
Intranasal · 2–3×/day during stress / cognitive demand
01Mechanism of Action
Parameter
Pancragen
Selank
Primary target
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014
Pathway
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007
Downstream effect
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007Zaderej 2014
Feedback intact?
Yes — preserves physiological glucose-insulin response
No GABA-receptor binding; no dependence reportedMedvedev 2007
Origin
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014
Antibody development
—
—
02Dosage Protocols
Parameter
Pancragen
Selank
Primate dose (rhesus macaque)
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
—
Effective concentration (in vitro)
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
—
Evidence basis
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Human-mechanistic + Russian clinical trialsMedvedev 2007
Diabetes model
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
—
Lower / starter dose
—
75 mcg / dose
Duration
—
10–14 day cycles, repeated as needed
Reconstitution
—
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
—
Morning + early afternoon preferred
Half-life
—
Short (minutes plasma); CNS effect lasts ~3 hr
04Side Effects & Safety
Parameter
Pancragen
Selank
Reported adverse events
None documented in primate studies
—
Human safety data
No published human trials; clinical use limited to Russian gerontology protocols
—
Nasal irritation
—
Mild burning or congestion (transient)
Cognitive impairment
—
None — opposite effect (enhancement)
Allergic reaction
—
Rare hypersensitivity
Long-term safety
—
Limited Western RCT data
Pregnancy / OB
—
Avoid — insufficient data
Absolute Contraindications
Pancragen
—Selank
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
Relative Contraindications
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
Selank
- ·Active autoimmune disease (theoretical via immunomodulation)
05Administration Protocol
Parameter
Pancragen
Selank
1. Reconstitution
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Route
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.
3. Timing
No specific timing constraints documented. Administered once daily in primate protocols.
Morning + early afternoon for cognitive demand; PRN for acute anxiety.
4. Cycle structure
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
Refrigerate after reconstitution; ≤30 days. Light-protected.
5. Caveat
—
Avoid co-administration with strong sedatives or other anxiolytics initially.